{
    "name": "lanadelumab",
    "comment": "Rx",
    "other_names": [
        "Takhzyro",
        "lanadelumab-flyo"
    ],
    "classes": [
        "Kallikrein Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/takhzyro-lanadelumab-1000243",
    "pregnancy": {
        "common": [
            "There are no available data regarding use in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Monoclonal antibodies are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy",
                    "An enhanced prenatal and postnatal development study conducted in pregnant monkeys at doses resulting in exposures of up to 33 times the exposure achieved (on an AUC basis) at the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of lanadelumab in human milk, its effects on the breastfed infant, or its effects on milk production",
            "Detected in the milk of lactating cynomolgus monkeys at ~0.2% of the maternal plasma concentration",
            "Consider the development and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions reported; if severe hypersensitivity reaction occurs, discontinue lanadelumab and institute appropriate treatment"
            ],
            "specific": [
                {
                    "type": "Interaction with aPPT assay",
                    "description": [
                        "Can increase activated partial thromboplastin time (aPTT) owing to an interaction with the aPTT assay",
                        "Reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system",
                        "Inhibition of plasma kallikrein by lanadelumab can increase aPTT in this assay"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site reaction",
            "percent": "56"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "44"
        },
        {
            "name": "Headache",
            "percent": "33"
        },
        {
            "name": "Myalgia",
            "percent": "11"
        },
        {
            "name": "Injection site reaction",
            "percent": "45"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "31"
        },
        {
            "name": "Headache",
            "percent": "21"
        },
        {
            "name": "Rash",
            "percent": "4"
        },
        {
            "name": "Dizziness",
            "percent": "4"
        },
        {
            "name": "Diarrhea",
            "percent": "4"
        },
        {
            "name": "Rash",
            "percent": "10"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        }
    ]
}